Literature DB >> 7865193

Economics and schizophrenia: the real cost.

L M Davies1, M F Drummond.   

Abstract

The total direct cost of treating schizophrenia in the UK is 397 million pounds, or 1.6% of the total health care budget. Hospital-based and community-based residential care accounts for nearly three-quarters of these costs, while drugs account for only 5%. A conservative estimate of the indirect annual costs of lost production is in the region of 1.7 billion pounds. The heterogeneity of the disease and its outcome means that average treatment costs per person with schizophrenia should be treated with caution; 97% of direct costs are incurred by less than half the patients. Therefore, treatments which reduce the dependence and disability of those most severely affected by schizophrenia are likely to have a large effect on the total cost of the disease to society and may therefore be cost-effective, even though they appear expensive initially.

Entities:  

Mesh:

Year:  1994        PMID: 7865193

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  40 in total

1.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 2.  Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.

Authors:  Alan Haycox
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.

Authors:  P S Chue; Bart Heeg; Erik Buskens; Ben A van Hout
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  The cost-effectiveness of clozapine: a survey of the literature.

Authors:  S Morris; T Hogan; A McGuire
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

5.  Care models for discharged psychiatric patients. Community based care is superior to conventional care.

Authors:  S P Sashidharan; M Smyth
Journal:  BMJ       Date:  1998-07-25

Review 6.  Psychiatric stigma: past, passing and to come.

Authors:  P Byrne
Journal:  J R Soc Med       Date:  1997-11       Impact factor: 5.344

7.  Predictors of clinical and social outcomes after hospitalization in schizophrenia.

Authors:  P R Menezes; L C Rodrigues; A H Mann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 8.  Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective.

Authors:  Mauro Percudani; Corrado Barbui; Michele Tansella
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Efficacy and tolerability of olanzapine in patients with schizophrenia in lithuania: A 13-week, multicenter, open-label, nonrandomized study.

Authors:  Valentinas Maciulis; Istvan Bitter; Raimundas Milasiunas; Algirdas Dembinskas; Liaudminas Radavicius; Algirdas Kaunas; Martin Dossenbach; Daniel Walker
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

10.  Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Authors:  Pierre Chue
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.